Engineered immune cells take on tough cancers in first human trial
NCT ID NCT07488923
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check the treatment's safety and to see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ML261 (a type of CAR T-cell therapy that targets DLL3 on cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for people with certain hard-to-treat lung and neuroendocrine cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human trial, so safety and effectiveness are unknown. There is a risk of serious side effects, and the therapy may not work for many participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee, 37203, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75235, United States